All In Biotech

Drug Trial Radar · NCT07211958

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 468 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

468

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Jun 2029

Study completion Jan 2031

Sponsor

Lead sponsor
Syndax PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.

Conditions

  • Acute Myeloid Leukemias

Interventions

  • RevumenibDrug

    Participants will receive revumenib orally.

  • PlaceboDrug

    Participants will receive placebo (non-active agent) orally.

  • Intensive Chemotherapy RegimenDrug

    Participants will receive an intensive chemotherapy regimen of cytarabine and daunorubicin by intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free SurvivalTime frame: Up to 2 years
  2. Measurable Residual Disease Complete Remission RateTime frame: Up to 2 years

Locations

173 sites in 23 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Goodyear, Arizona · Recruiting

  • Clinical Trial Site

    Duarte, California · Recruiting

  • Clinical Trial Site

    Farmington, Connecticut · Recruiting

  • Clinical Trial Site

    Tampa, Florida · Recruiting

  • Clinical Trial Site

    Indianapolis, Indiana · Recruiting

  • Clinical Trial Site

    Shreveport, Louisiana · Recruiting

  • Clinical Trial Site

    Morristown, New Jersey · Recruiting

  • Clinical Trial Site

    Chapel Hill, North Carolina · Recruiting

  • Clinical Trial Site

    Providence, Rhode Island · Recruiting

  • Clinical Trial Site

    Greenville, South Carolina · Recruiting

  • Clinical Trial Site

    Houston, Texas · Recruiting

  • Clinical Trial Site

    Buenos Aires, Argentina · Recruiting

  • Clinical Trial Site

    Salta, Argentina · Recruiting

  • Clinical Trial Site

    Adrogué, Buenos Aires, Argentina · Recruiting

  • Clinical Trial Site

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Clinical Trial Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Clinical Trial Site

    Gosford, Australia · Recruiting

  • Clinical Trial Site

    Wollongong, Australia · Recruiting

  • Clinical Trial Site

    Kingswood, New South Wales, Australia · Recruiting

  • Clinical Trial Site

    Kogarah, New South Wales, Australia · Recruiting

  • Clinical Trial Site

    Randwick, New South Wales, Australia · Recruiting

  • Clinical Trial Site

    Douglas, Queensland, Australia · Recruiting

  • Clinical Trial Site

    South Brisbane, Queensland, Australia · Recruiting

  • Clinical Trial Site

    Melbourne, Victoria, Australia · Recruiting

  • Clinical Trial Site

    Parkville, Victoria, Australia · Recruiting

  • Clinical Trial Site

    Nedlands, Western Australia, Australia · Recruiting

  • Clinical Trial Site

    Perth, Western Australia, Australia · Recruiting

  • Clinical Trial Site

    Linz, Austria · Recruiting

  • Clinical Trial Site

    Vienna, Austria · Recruiting

  • Clinical Trial Site

    Klagenfurt, Kaerten, Austria · Recruiting

  • Clinical Trial Site

    Sankt Pölten, Lower Austria, Austria · Recruiting

  • Clinical Trial Site

    Graz, Styria, Austria · Recruiting

  • Clinical Trial Site

    Leoben, Styria, Austria · Recruiting

  • Clinical Trial Site

    Innsbruck, Tyrol, Austria · Recruiting

  • Clinical Trial Site

    Ghent, Belgium · Recruiting

  • Clinical Trial Site

    Jaú, Brazil · Recruiting

  • Clinical Trial Site

    Porto Alegre, Brazil · Recruiting

  • Clinical Trial Site

    São Paulo, Estado de Bahia, Brazil · Recruiting

  • Clinical Trial Site

    Fortaleza, Paraná, Brazil · Recruiting

  • Clinical Trial Site

    Barretos, São Paulo, Brazil · Recruiting

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.